Non-Invasive Heart Failure Monitoring in Hospitalized Patients
Official title: Hemodynamic Observational Study in Patients With Heart Failure Using a Non-Invasive Multi-Modal Sensing Device (HOSP-HF)
Run by Acorai AB · NCT07671742 · Data updated 2026-11-12
This study tests whether daily non-invasive thoracic measurements from the Acorai Device 1.0 can relate to health outcomes for adults hospitalized with heart failure.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Acorai AB Industry-sponsored |
| Locations | 1 site (Lund) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | March 1, 2027 |
| Study ends | April 1, 2027 |
| Registry record updated | June 26, 2026 |
| Trial ID | NCT07671742 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) hospitalized for primary heart failure with congestion requiring therapy, able to consent.
✕Probably not a fit
Patients who do not experience heart failure-related readmission or mortality within 90 days or whose health status does not correlate with the device measurements may see no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, multicenter observational study follows adults admitted with heart failure to see how non-invasive thoracic sensor data from the Acorai Device 1.0 relate to clinical data and outcomes. Participants have daily five-minute recordings during hospitalization and are tracked for 90 days after discharge for heart failure hospitalization or death. The device records multimodal signals without altering clinical care or management. Researchers will compare sensor measurements with demographics, vitals, labs, imaging, and outcomes to identify potential associations. No diagnostic or therapeutic procedures are introduced by the study and data are collected from medical records where available.
Why it matters
Potential benefit: If associations are found, the device could help clinicians understand congestion and hemodynamics with less burden on patients.
How similar studies have gone: Previous non-invasive hemodynamic sensing in heart failure has shown informative signals, but this study adds prospective, daily in-hospital monitoring to assess predictive associations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Hospitalization for primary heart failure, defined as new or worsening heart failure symptoms with objective evidence of congestion requiring initiation or intensification of heart failure-specific therapy * Ability to provide written informed consent Exclusion Criteria: * Any discretionary exclusion where the inclusion of the subject is deemed to pose potential risks to the subject's well-being or is likely to comprise the compliant performance of the study. * Pregnancy or lactation (as confirmed by self-report or medical documentation) * Presence of a skin rash or open wound in the area where the Acorai Device model 1.0 will be applied * Any other condition that, in the opinion of the investigator, would preclude the subject from participating in the study or may affect the integrity of the data
Where it's running
-
Skåne University Hospital
Lund, Sweden Recruiting
Study contacts
- Study coordinator: Warka AlHassani
- Email: warka.alhassani@acorai.com
- Phone: +46 709 72 60 97
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.